These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36861394)

  • 21. Registered clinical studies investigating psychedelic drugs for psychiatric disorders.
    Siegel AN; Meshkat S; Benitah K; Lipsitz O; Gill H; Lui LMW; Teopiz KM; McIntyre RS; Rosenblat JD
    J Psychiatr Res; 2021 Jul; 139():71-81. PubMed ID: 34048997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers.
    Kious B; Schwartz Z; Lewis B
    J Psychopharmacol; 2023 Jan; 37(1):45-48. PubMed ID: 36377548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychedelic Drug Legislative Reform and Legalization in the US.
    Siegel JS; Daily JE; Perry DA; Nicol GE
    JAMA Psychiatry; 2023 Jan; 80(1):77-83. PubMed ID: 36477830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review.
    Yu Z; Burback L; Winkler O; Xu L; Dennett L; Vermetten E; Greenshaw A; Li XM; Milne M; Wang F; Cao B; Winship IR; Zhang Y; Chan AW
    Front Psychiatry; 2024; 15():1386321. PubMed ID: 38807690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
    Majić T; Schmidt TT; Gallinat J
    J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts.
    Wilson-Poe A; Hoffman K; Pertl K; Luoma J; Bazinet A; Stauffer C; McCarty D; Korthuis P
    J Psychoactive Drugs; 2024 Sep; ():1-8. PubMed ID: 39269313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychoactive Drugs in the Management of Post Traumatic Stress Disorder: A Promising New Horizon.
    Elsouri KN; Kalhori S; Colunge D; Grabarczyk G; Hanna G; Carrasco C; Aleman Espino A; Francisco A; Borosky B; Bekheit B; Ighanifard M; Astudillo AA; Demory Beckler M
    Cureus; 2022 May; 14(5):e25235. PubMed ID: 35747039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
    Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
    PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychedelic drugs for psychiatric disorders.
    da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
    J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of Psychedelic Experience: A Thematic Analysis.
    McCartney AM; McGovern HT; De Foe A
    J Psychoactive Drugs; 2023; 55(4):411-419. PubMed ID: 36197103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minorities' Diminished Psychedelic Returns: Income and Educations Impact on Whites, Blacks, Hispanics, and Asians.
    Vina SM
    J Racial Ethn Health Disparities; 2024 May; ():. PubMed ID: 38753105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications.
    Kraehenmann R
    Curr Neuropharmacol; 2017; 15(7):1032-1042. PubMed ID: 28625125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review of potential psychedelic treatments for PTSD.
    Henner RL; Keshavan MS; Hill KP
    J Neurol Sci; 2022 Aug; 439():120302. PubMed ID: 35700643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns.
    Johnston CB; Mangini M; Grob C; Anderson B
    Am J Geriatr Psychiatry; 2023 Jan; 31(1):44-53. PubMed ID: 36184377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis.
    Li JR; Chiang KT; Kao YC; Yu CL; Yang FC; Liang CS; Hsu TW
    J Affect Disord; 2025 Jan; 369():421-428. PubMed ID: 39389119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice.
    Gorman I; Nielson EM; Molinar A; Cassidy K; Sabbagh J
    Front Psychol; 2021; 12():645246. PubMed ID: 33796055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences.
    Williams MT; Davis AK; Xin Y; Sepeda ND; Grigas PC; Sinnott S; Haeny AM
    Drugs (Abingdon Engl); 2021; 28(3):215-226. PubMed ID: 34349358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Past and Future of Psychedelic Science: An Introduction to This Issue.
    Doblin RE; Christiansen M; Jerome L; Burge B
    J Psychoactive Drugs; 2019; 51(2):93-97. PubMed ID: 31132970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The epistemic innocence of psychedelic states.
    Letheby C
    Conscious Cogn; 2016 Jan; 39():28-37. PubMed ID: 26675408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.